Sunitinib in refractory adrenocortical-carcinoma patients progressing after cytotoxic chemotherapy
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2013
At a glance
- Drugs Sunitinib (Primary)
- Indications Adrenal cancer
- Focus Therapeutic Use
- Acronyms SIRAC
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
- 01 Jun 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2007-001165-15).
- 29 Aug 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004039).